Market Research Report

Prostate Cancer Drug Pipeline Update 2012

cover Published by BioSeeker Group AB
Published Product code 171784
Price

Introduction

Abstract

Executive Summary

BioSeeker Group have identified 332 companies plus partners who are today developing 402 drugs targeting prostate cancer in development. Across 231 different targets. In addition, there are 5 suspended drugs and another 169 drugs where development has been ceased.

For busy executives within Pharma, Biotech and Investment companies who know they need to stay on top of the developmental environment in their field, we offer the Drug Pipeline update series.

You get detailed, world-wide drug pipeline information, delivered in an unbiased and independent pipeline progress analysis for each identified drug.

Buying the Prostate Cancer Drug Pipeline Update 2012 will mean you have this important data at your fingertips and ensure that you can:

  • Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
  • Find competitors, collaborations partners, M&A candidates etc. and track them by their products.
  • Jump start competitive drug intelligence operations
  • Benchmark your own development against world wide data
  • Compare portfolio and therapy focus with your peers
  • Speed up pro-active in-/outlicensing strategy work

Some facts about Prostate Cancer Drug Pipeline Update 2012

Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. The prostate cancer market is reaching maturity, and major players` sales have been eroded by the launch of various LHRH agonist depot formulations. Safety concerns with AstraZeneca`s Casodex (bicalutamide) have also seen a significant proportion of physicians switching to alternatives. Establishing the optimal timing of antihormonal therapy will provide the key to market growth.

There are today 332 companies plus partners developing 402 drugs targeting prostate cancer in development. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 169 drugs. Prostate Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 231 different targets. These targets are further categorized on in the software application by 63 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.

Table of Contents

Table of Contents

Details from Prostate Cancer Drug Pipeline Update 2012 at a glance

This short overview shows actual findings from the Prostate Cancer Drug Pipeline Update 2012 report.

Investigators

Includes more than 332 principal investigators plus their collaborators. There is direct access from inside the application to web pages of all principal investigators.

Note: You are able to sort and find drugs according to investigators and partners from drop-down menus in the application. You may also sort and find drugs according to country of investigator.

Drug name & Synonyms

Lists commercial, generic and code names for drugs.

Developmental stage

This Drug Pipeline Update contains 402 drugs in development for the treatment of prostate cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs

  • Marketed# 29
  • Pre-registration# 2
  • Phase III# 24
  • Phase II# 149
  • Phase I# 76
  • Preclinical# 118
  • No Data# 4
  • Suspended# 5
  • Ceased# 169

Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.

Indications

Included prostate cancer drugs are also in development for 194 other indications, where of 88 are different cancer indications.

Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.

Targets

Identified drugs are linked to more than 231 different targets, divided into 63 classifications of molecular function:

  • Acid phosphatase activity
  • Auxiliary transport protein activity
  • Calcium ion binding
  • Carboxy-lyase activity
  • Carboxypeptidase activity
  • Catalytic activity
  • Cell adhesion molecule activity
  • Chaperone activity
  • Chemokine activity
  • Complement activity
  • Cysteine-type peptidase activity
  • Cytokine activity
  • DNA binding
  • DNA repair protein
  • DNA topoisomerase activity
  • DNA-directed DNA polymerase activity
  • Extracellular ligand-gated ion channel activity
  • Extracellular matrix structural constituent
  • G-protein coupled receptor activity
  • Growth factor activity
  • GTPase activator activity
  • Hormone activity
  • Hydrolase activity
  • Intracellular ligand-gated ion channel activity
  • Ion channel activity
  • Isomerase activity
  • Kinase activity
  • Ligand-dependent nuclear receptor activity
  • Ligase activity
  • Lipid kinase activity
  • Lipid phosphatase activity
  • Metallopeptidase activity
  • MHC class I receptor activity
  • Molecular function unknown
  • Motor activity
  • Oxidoreductase activity
  • Peptidase activity
  • Peptide hormone
  • Peroxidase activity
  • Phosphoric diester hydrolase activity
  • Protein binding
  • Protein serine/threonine kinase activity
  • Protein tyrosine phosphatase activity
  • Protein-tyrosine kinase activity
  • Receptor activity
  • Receptor binding
  • Receptor signaling complex scaffold activity
  • Receptor signaling protein serine/threonine kinase activity
  • RNA binding
  • RNA-directed DNA polymerase activity
  • Serine-type peptidase activity
  • Structural constituent of cytoskeleton
  • Superoxide dismutase activity
  • Transcription factor activity
  • Transcription regulator activity
  • Transferase activity
  • Translation regulator activity
  • Transmembrane receptor activity
  • Transmembrane receptor protein tyrosine kinase activity
  • Transporter activity
  • Ubiquitin-specific protease activity
  • Unknown
  • Voltage-gated ion channel activity

Identified targets are categorized into 25 different primary and alternate sub-cellular localizations: Cell surface Centrosome Clathrin-coated vesicle Cytoplasm Cytoplasmic vesicle Cytoskeleton Cytosol Endoplasmic reticulum Endosome Extracellular Golgi apparatus Integral to membrane Lysosome Microtubule Mitochondrial membrane Mitochondrion Nuclear membrane Nucleolus Nucleus Perinuclear region Perinuclear vesicle Peroxisome Plasma membrane Secreted Secretory granule

Note: You are able to find and sort drugs according to target gene name, molecular function of target, and target localization from drop-down menus in the application.

Target Expression Profile

Direct links are provided from inside the application to 316 protein expression profiles of 196 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:

  • 48 different normal tissue types
  • 20 different types of cancer
  • 47 cell lines
  • 12 samples of primary blood cells

Pathway Referals

Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG and NetPath.

  • BioCarta# 239 Pathways
  • KEGG# 164 Pathways
  • NetPath# 25 Signaling Pathways

Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.

Mechanism

In total there are different drug mechanism of action represented in this Drug Pipeline Update.

Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.

Compound

Identified drug compounds are described by:

Compound type, Chemical name, CAS Number and molecular weight

Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.

The Drug Profiles: Progress analysis and review of drug development.

Prostate Cancer Drug Pipeline Update 2012 provides you with a profile for each identified drug. A typical drug profile reports on, depending on stage of development and available information:

Drug Name & Synonyms

Presentation of drug name and synonyms.

Principal Investigator & Partners

Presentation of principal investigator and partners.

Target and Molecular Function of Target

Described target(s) is/are presented with:

  • Official Gene Symbol - Official Gene Name [Species/Homo Sapiens] - Molecular Function

Target Localization

Described target(s) is/are presented with primary and alternate localizations.

Target Expression Profiles

Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:

  • 48 different normal tissue types
  • 20 different types of cancer
  • 47 cell lines
  • 12 samples of primary blood cells

Targeted Pathways

Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, and NetPath.

Mechanism

Drug mechanism of action

Developmental Projects

Summary field of developmental projects for the drug, including indication, developmental stage and status.

Example:

  • Cancer, myeloma - Phase II Clinical Trial - Active
  • Cancer, prostate - Phase III Clinical Trial - Ceased

Drug Description

Short introduction to drug

Compound Data

Compound type, Chemical name, CAS Number and molecular weight.

Patent Data

Available patent information related to the drug is presented here.

Analysis

  • Business & Markets
  • Collaborations and deals
  • Approvals and submissions
  • Analyst comments

Phase III Data

Available Phase III development data, developmental history and scientific data.

Phase II Data

Available Phase II development data, developmental history and scientific data.

Phase I Data

Available Phase I development data, developmental history and scientific data.

Preclinical Data

Available preclinical development data, developmental history and scientific data.

Licensing Information

Availability for licensing.

About the unique Drug Pipeline Update Software Application

After purchase, the Drug Pipeline Update is delivered to you via electronic download in a powerful yet easy to use desktop application which requires no installation.

Find and sort drugs by twelve different parameters plus free text search field. Our dynamic report generator lets you easily and quickly generate HTML drug profile reports directly in your web browser, whether it is a single drug profile or your own report selection of drugs that match your criteria.

Application Features

Use 13 different parameters, available in drop-down menus, to find and sort among drugs

  • Drug status
  • Clinical Trial Status
  • Principle Investigator
  • Partners
  • Indication
  • Developmental Stage
  • Compound Type
  • Mechanism
  • Target
  • Molecular Function of Target
  • Target Localization
  • Targeted Pathways
  • Free text search of entire drug profile contents

Direct linkage from inside the application to related internet resources

  • Drug data is linked to search engines like Google and PubMed
  • Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, and NetPath
  • Direct links to company web pages of principal investigators

Dynamic Report Generator

Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer), whether it is a single drug profile or an entire search you want have a report of.

System Requirements

  • Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
  • Browser Application (Internet Explorer)
  • Internet access (to access related internet resources)

Prostate Cancer Drug Pipeline Update 2012 published by BioSeeker Group AB in April 22, 2013. This report price starts from US $ 2249.

The contents of this page may be different from the latest version. Please contact us for details.

Back to Top